FDA approves NDA for sodium fluoride F18 injection

Justine Varieur Cadet | | Health Imaging | Molecular Imaging
The FDA has approved a new drug application (NDA) for use of a new strength of a previously approved drug, sodium fluoride F18 (18F-NaF) injection, in bone scans. The National Cancer Institute and the National Institutes of Health submitted the NDA.

Knoxville, Tenn.-based PETNet Solutions, a wholly-owned subsidiary of Siemens Healthcare, is the only manufacturer included in the NDA for 18F-NaF injection at this time.

PETNet said this could increase its radiopharmaceutical manufacturing and distribution capabilities, and lays the foundation for manufacturing of new molecular imaging biomarkers as they are commercialized. The company operates a network of PET radiopharmaceutical production facilities with 54 production and distribution centers globally.

Justine Varieur Cadet

Related Content

Repurposed radiotracer lights up treatment-resistant tumors 'like a Christmas tree'
Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.